Quick Answer
Ocean Biomedical, Inc. reported Net Income of -$9.48 million for fiscal year 2024.
Ocean Biomedical, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Net Income | -$9.48M +91.7% |
-$114.47M -559.4% |
-$17.36M | — |
| Diluted EPS | -$0.34 +92.2% |
-$4.35 -487.8% |
-$0.74 | — |
| Total Assets | $902.0K -83.6% |
$5.50M +198.6% |
$1.84M -98.3% |
$108.65M |
| Stockholders Equity | -$96.26M -6.1% |
-$90.76M -738.9% |
-$10.82M -62.4% |
-$6.66M |
| R&D Expense | $26.0K -96.3% |
$709.0K -91.6% |
$8.41M | — |
| Operating Income | -$3.80M +62.8% |
-$10.21M +36.6% |
-$16.12M | — |
| Shares Outstanding | 34.87M +0.6% |
34.65M +48.4% |
23.36M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | March 31, 2025 | -$8.24M | -163.4% | -49.1% |
| Diluted EPS | March 31, 2025 | -$0.09 | -118.8% | +55.0% |
| Total Assets | March 31, 2025 | $1.58M | -46.3% | +75.4% |
| Stockholders Equity | March 31, 2025 | -$92.40M | -21.9% | +5.3% |
| R&D Expense | March 31, 2025 | $18.0K | -30.8% | -30.8% |
| Operating Income | March 31, 2025 | -$958.0K | -61.0% | -24.7% |
| Shares Outstanding | March 31, 2025 | 166.01M | +376.8% | +376.1% |
- Ocean Biomedical, Inc. reported Net Income of -$9.48 million for fiscal year 2024.
- Ocean Biomedical, Inc. showed an increase of +91.7% in Net Income compared to the prior fiscal year.
- Ocean Biomedical, Inc. reported Diluted EPS of $0.34 per share (loss) for fiscal year 2024.
- Ocean Biomedical, Inc. showed an increase of +92.2% in Diluted EPS compared to the prior fiscal year.
- Ocean Biomedical, Inc. reported Total Assets of $902.0 thousand for fiscal year 2024.
- Ocean Biomedical, Inc. showed a decrease of -83.6% in Total Assets compared to the prior fiscal year.
- Ocean Biomedical, Inc. reported Stockholders Equity of -$97.62 million for fiscal year 2024.
- Ocean Biomedical, Inc. showed a decrease of -1.4% in Stockholders Equity compared to the prior fiscal year.
- Ocean Biomedical, Inc. reported R&D Expense of $26.0 thousand for fiscal year 2024.
- Ocean Biomedical, Inc. showed a decrease of -96.3% in R&D Expense compared to the prior fiscal year.
- Ocean Biomedical, Inc. reported Operating Income of -$3.80 million for fiscal year 2024.
- Ocean Biomedical, Inc. showed an increase of +62.8% in Operating Income compared to the prior fiscal year.
- Ocean Biomedical, Inc. reported Shares Outstanding of 34.87 million shares for fiscal year 2024.
- Ocean Biomedical, Inc. showed an increase of +0.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: